Beryl McCormick1, Kathryn A Winter2, Wendy Woodward3, Henry M Kuerer3, Nour Sneige3, Eileen Rakovitch4, Barbara L Smith5, Isabelle Germain6, Alan C Hartford7, Mark A O'Rourke8, Eleanor M Walker9, Eric A Strom3, Judith O Hopkins10, Lori J Pierce11, Anthony T Pu12, Kenneth N M Sumida13, Danny Vesprini14, Jennifer Moughan2, Julia R White14. 1. Memorial Sloan Kettering Cancer Center, New York, NY. 2. NRG Oncology Statistics and Data Management Center, Philadelphia, PA. 3. The University of Texas MD Anderson Cancer Center, Houston, TX. 4. Odette Cancer Centre-Sunnybrook Health Sciences Centre, Toronto, ON, Canada. 5. Massachusetts General Hospital Cancer Center, Boston, MA. 6. CHU de Quebec-L'Hotel-Dieu de Quebec, Quebec City, QC, Canada. 7. Dartmouth-Hitchcock Medical Center, Lebanon, NH. 8. Greenville CCOP-Cancer Centers of The Carolinas-Eastside, Greenville, SC. 9. Henry Ford Hospital Rogel Cancer Center, Detroit, MI. 10. Southeast Clinical Oncology Research (SCOR) Consortium NCORP, Winston-Salem, NC. 11. University of Michigan, Ann Arbor, MI. 12. Radiological Associates of Sacramento, Sacramento, CA. 13. University of Hawaii Cancer Center MBCCOP, Honolulu, HI. 14. Ohio State University Comprehensive Cancer Center, Columbus, OH.
Abstract
PURPOSE: To our knowledge, NRG/RTOG 9804 is the only randomized trial to assess the impact of whole breast irradiation (radiation therapy [RT]) versus observation (OBS) in women with good-risk ductal carcinoma in situ (DCIS), following lumpectomy. Long-term results focusing on ipsilateral breast recurrence (IBR), the primary outcome, are presented here. PATIENTS AND METHODS: Eligible patients underwent lumpectomy for DCIS that was mammogram detected, size ≤ 2.5 cm, final margins ≥ 3 mm, and low or intermediate nuclear grade. Consented patients were randomly assigned to RT or OBS. Tamoxifen use was optional. Cumulative incidence was used to estimate IBR, log-rank test and Gray's test to compare treatments, and Fine-Gray regression for hazard ratios (HRs). RESULTS: A total of six hundred thirty-six women were randomly assigned from 1999 to 2006. Median age was 58 years and mean pathologic DCIS size was 0.60 cm. Intention to use tamoxifen was balanced between arms (69%); however, actual receipt of tamoxifen varied, 58% RT versus 66% OBS (P = .05). At 13.9 years' median follow-up, the 15-year cumulative incidence of IBR was 7.1% (95% CI, 4.0 to 11.5) with RT versus 15.1% (95% CI, 10.8 to 20.2) OBS (P = .0007; HR = 0.36; 95% CI, 0.20 to 0.66); and for invasive LR was 5.4% (95% CI, 2.7 to 9.5) RT versus 9.5% (95% CI, 6.0 to 13.9) OBS (P = .027; HR = 0.44; 95% CI, 0.21 to 0.91). On multivariable analysis, only RT (HR = 0.34; 95% CI, 0.19 to 0.64; P = .0007) and tamoxifen use (HR = 0.45; 95% CI, 0.25 to 0.78; P = .0047) were associated with reduced IBR. CONCLUSION: RT significantly reduced all and invasive IBR for good-risk DCIS with durable results at 15 years. These results are not an absolute indication for RT but rather should inform shared patient-physician treatment decisions about ipsilateral breast risk reduction in the long term following lumpectomy.
PURPOSE: To our knowledge, NRG/RTOG 9804 is the only randomized trial to assess the impact of whole breast irradiation (radiation therapy [RT]) versus observation (OBS) in women with good-risk ductal carcinoma in situ (DCIS), following lumpectomy. Long-term results focusing on ipsilateral breast recurrence (IBR), the primary outcome, are presented here. PATIENTS AND METHODS: Eligible patients underwent lumpectomy for DCIS that was mammogram detected, size ≤ 2.5 cm, final margins ≥ 3 mm, and low or intermediate nuclear grade. Consented patients were randomly assigned to RT or OBS. Tamoxifen use was optional. Cumulative incidence was used to estimate IBR, log-rank test and Gray's test to compare treatments, and Fine-Gray regression for hazard ratios (HRs). RESULTS: A total of six hundred thirty-six women were randomly assigned from 1999 to 2006. Median age was 58 years and mean pathologic DCIS size was 0.60 cm. Intention to use tamoxifen was balanced between arms (69%); however, actual receipt of tamoxifen varied, 58% RT versus 66% OBS (P = .05). At 13.9 years' median follow-up, the 15-year cumulative incidence of IBR was 7.1% (95% CI, 4.0 to 11.5) with RT versus 15.1% (95% CI, 10.8 to 20.2) OBS (P = .0007; HR = 0.36; 95% CI, 0.20 to 0.66); and for invasive LR was 5.4% (95% CI, 2.7 to 9.5) RT versus 9.5% (95% CI, 6.0 to 13.9) OBS (P = .027; HR = 0.44; 95% CI, 0.21 to 0.91). On multivariable analysis, only RT (HR = 0.34; 95% CI, 0.19 to 0.64; P = .0007) and tamoxifen use (HR = 0.45; 95% CI, 0.25 to 0.78; P = .0047) were associated with reduced IBR. CONCLUSION: RT significantly reduced all and invasive IBR for good-risk DCIS with durable results at 15 years. These results are not an absolute indication for RT but rather should inform shared patient-physician treatment decisions about ipsilateral breast risk reduction in the long term following lumpectomy.
Authors: Carol E DeSantis; Jiemin Ma; Mia M Gaudet; Lisa A Newman; Kimberly D Miller; Ann Goding Sauer; Ahmedin Jemal; Rebecca L Siegel Journal: CA Cancer J Clin Date: 2019-10-02 Impact factor: 508.702
Authors: Troy Bremer; Pat W Whitworth; Rakesh Patel; Jess Savala; Todd Barry; Stephen Lyle; Glen Leesman; Steven P Linke; Karin Jirström; Wenjing Zhou; Rose-Marie Amini; Fredrik Wärnberg Journal: Clin Cancer Res Date: 2018-07-27 Impact factor: 12.531
Authors: Stefan O Emdin; Bengt Granstrand; Anita Ringberg; Kerstin Sandelin; Lars-Gunnar Arnesson; Hans Nordgren; Harald Anderson; Hans Garmo; Lars Holmberg; Arne Wallgren Journal: Acta Oncol Date: 2006 Impact factor: 4.089
Authors: Irene L Wapnir; James J Dignam; Bernard Fisher; Eleftherios P Mamounas; Stewart J Anderson; Thomas B Julian; Stephanie R Land; Richard G Margolese; Sandra M Swain; Joseph P Costantino; Norman Wolmark Journal: J Natl Cancer Inst Date: 2011-03-11 Impact factor: 13.506
Authors: S E Pinder; C Duggan; I O Ellis; J Cuzick; J F Forbes; H Bishop; I S Fentiman; W D George Journal: Br J Cancer Date: 2010-06-01 Impact factor: 7.640
Authors: M J Silverstein; B F Cohlan; E D Gierson; M Furmanski; P Gamagami; W J Colburn; B S Lewinsky; J R Waisman Journal: Eur J Cancer Date: 1992 Impact factor: 9.162
Authors: Wendy A Woodward; Nour Sneige; Kathryn Winter; Henry Mark Kuerer; Clifford Hudis; Eileen Rakovitch; Barbara L Smith; Lori J Pierce; Isabelle Germano; Anthony T Pu; Eleanor M Walker; David Lawrence Grisell; Julia R White; Beryl McCormick Journal: J Clin Pathol Date: 2014-09 Impact factor: 3.411
Authors: Fredrik Wärnberg; Per Karlsson; Erik Holmberg; Kerstin Sandelin; Pat W Whitworth; Jess Savala; Todd Barry; Glen Leesman; Steven P Linke; Steven C Shivers; Frank Vicini; Chirag Shah; Sheila Weinmann; Gregory Bruce Mann; Troy Bremer Journal: Cancers (Basel) Date: 2021-12-03 Impact factor: 6.639